Quatre Bornes

This research aims to evaluate the safety and effectiveness of Multi-Gyn FemiTotal, a vaginal gel, for treating and preventing bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) in women. The study will include women diagnosed with itching symptoms of VVC and BV confirmed by Amsel criteria. The primary goal is to assess how well the gel treats BV and relieves VVC symptoms 21 days after starting treatment, with a focus on symptom relief and infection control.

Researchers are evaluating the safety and effectiveness of a cream called RV4421B-EV0407, which is designed to treat various types of eczema, including atopic eczema, contact eczema, and chronic hand eczema. This cream is already available in several countries. The study includes both children and adults of diverse ethnic backgrounds, including individuals with dark skin, and monitors its use over a period of 12 weeks with a follow-up. Participants will apply the RV4421B-EV0407 cream on affected skin areas, typically 5 to 15 minutes after using topical corticosteroids if applicable. The maximum application period of the cream is 87 days. The study involves 5 visits: an initial inclusion visit on Day 1, a phone check between Days 8 and 15, and intermediate visits on Days 29 and 57, followed by a final visit on Day 85. During the study, participants will undergo assessments to monitor how well the cream is tolerated on the treated areas by Day 85. Researchers will also track safety and treatment effects through these visits. The total participation duration is about 12 weeks, during which the skin condition and any reactions to the cream will be carefully observed.